I am an R&D scientist with expertise in human pluripotent stem cells, specializing in generating neurons and glia and using organoid technology to model their development. My academic journey culminated in a Ph.D., during which I developed and refined an innovative in vitro assay for modeling axonal projections using regionally patterned 3D assembloids. This approach enables the simulation of neural pathways and has advanced our understanding of retinal ganglion cell differentiation, axonal outgrowth, pathfinding, and regeneration. During this time, I also gained experience in genetic modification of pluripotent stem cells using CRISPR technology, creating reporter lines, disease models, and isogenic controls. In transitioning to industry, I focused on hPSC-derived endothelial cells to manufacture vasculogenic progenitor cells capable of forming new blood vessels in oxygen-starved tissues. I led the development of a three-dimensional vasculogenesis release assay for the final product, ensuring its quality and potency. In my current role, I am dedicated to advancing scientific progress and translating research into therapeutic solutions. My work centers on rapidly differentiating hPSCs into pure populations of human oligodendrocyte progenitor cells (hOPCs) and directing these cells to mature into myelinating oligodendrocytes. I am beginning to incorporate 3D neuron–oligodendrocyte co-cultures and spheroid assays to extend these findings beyond 2D systems and to evaluate differentiation and myelination capacity in more physiologically relevant contexts. This direction reflects my broader goal of developing advanced in vitro models that bridge the gap between reductionist assays and clinical translation, ultimately reducing reliance on animal models and strengthening the pipeline to successful clinical studies.